Biopharmaceutical Fermentation System Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 27.68 Billion
CAGR (2026-2031)	8.67%
Fastest Growing Segment	Antibiotics
Largest Market	North America
Market Size (2031)	USD 45.59 Billion

Market Overview

The Global Biopharmaceutical Fermentation System Market will grow from USD 27.68 Billion in 2025 to USD 45.59 Billion by 2031 at a 8.67% CAGR. Biopharmaceutical fermentation systems constitute specialized bioreactors and integrated control units designed to cultivate microorganisms, such as bacteria and fungi, for the large-scale production of therapeutic proteins, vaccines, and other biological products. The primary drivers supporting the growth of this market include the escalating global demand for biologics and biosimilars, the rapid expansion of contract development and manufacturing organization capabilities, and the increasing prevalence of chronic diseases necessitating biological interventions.

Robust financial commitment to drug development further underpins this sector's expansion. According to the European Federation of Pharmaceutical Industries and Associations, in 2024, the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe. Despite this positive investment climate, the market faces a significant challenge regarding the substantial capital expenditure and technical expertise required to establish and maintain regulatory-compliant upstream processing facilities.

Key Market Drivers

The rapid expansion of the biologics pipeline, driven by the escalating global prevalence of chronic diseases, serves as a primary catalyst for the adoption of biopharmaceutical fermentation systems. Manufacturers are heavily investing in upstream processing infrastructure to meet the soaring commercial requirements for recombinant proteins and monoclonal antibodies. This surge is necessitating the construction of large-scale facilities equipped with advanced bioreactors to ensure the continuous supply of metabolic and immunological treatments. According to Novo Nordisk, June 2024, in the 'Novo Nordisk to invest 4.1 billion USD in North Carolina' press release, the company announced plans to build a new manufacturing facility to expand production capacity for its treatments for chronic diseases.

Concurrently, the growth in outsourcing to Contract Development and Manufacturing Organizations accelerates market activity as pharmaceutical innovators seek to mitigate technical risks. CDMOs are continuously upgrading their fermentation lines with high-density bioreactors to accommodate diverse client portfolios ranging from vaccines to cell therapies. According to Samsung Biologics, October 2024, in the 'Third Quarter 2024 Financial Results', the company reported a cumulative consolidated revenue of KRW 3.2 trillion, reflecting increased client demand for manufacturing services. Beyond outsourcing, established players are expanding internal capacities; according to Sanofi, May 2024, in the press release 'Sanofi invests 1.1 billion euros in France', the entity committed these funds to create a new bioproduction site at Vitry-sur-Seine to double its monoclonal antibody production capacity.

Download Free Sample Report

Key Market Challenges

The substantial capital expenditure and technical expertise required to establish and maintain regulatory-compliant upstream processing facilities act as a significant constraint on the growth of the Global Biopharmaceutical Fermentation System Market. This high barrier to entry disproportionately affects small and medium-sized biopharmaceutical enterprises, which often lack the financial resilience to invest in expensive capital equipment and the sophisticated infrastructure needed for commercial-scale fermentation. Consequently, the market for these systems becomes heavily reliant on large pharmaceutical corporations and Contract Development and Manufacturing Organizations (CDMOs), effectively narrowing the potential customer base and stalling broader market adoption.

This financial pressure is exacerbated by a tightening funding environment that restricts the liquidity available for such capital-intensive infrastructure projects. When companies cannot secure sufficient backing, they are forced to delay or cancel plans for facility construction and equipment upgrades. According to the BioIndustry Association, in 2024, the biotech sector in the UK faced a challenging public market environment with zero initial public offerings (IPOs) recorded for the second consecutive year. This lack of access to public capital markets directly impedes the ability of growing companies to raise the necessary funds for expanding their manufacturing footprint, thereby hampering new orders for fermentation systems.

Key Market Trends

The Integration of Artificial Intelligence and Machine Learning is revolutionizing the Global Biopharmaceutical Fermentation System Market by transitioning operations towards intelligent, data-driven manufacturing. Market players are embedding AI algorithms into bioreactor control units to enable predictive maintenance and real-time metabolite monitoring, thereby minimizing batch failures and maximizing titer yields. This shift towards digitally mature infrastructure is exemplified by recent facility launches that prioritize smart technologies over traditional processing methods. According to Amgen, February 2024, in the 'Amgen opens AI-enabled Ohio biomanufacturing facility' press release, the company invested $365 million to establish a site featuring advanced automation and digital capabilities designed to optimize the reliability of biologic production.

Simultaneously, the Growing Emphasis on Sustainable and Green Bioprocessing Practices is influencing the design and operation of fermentation systems to align with rigorous environmental standards. Manufacturers are actively seeking bioreactor solutions and facility configurations that reduce carbon footprints and water consumption, pushing the market towards energy-efficient and renewable-compatible technologies. This strategic pivot is highlighted by industry leaders securing green energy infrastructure to power their upstream processing lines. According to Merck KGaA, January 2024, in the press release 'Merck and China Resources Power Enter into Long-Term Green Power Agreement', the entity finalized a ten-year contract to utilize 300 gigawatt hours of renewable electricity, underscoring the sector's commitment to decarbonizing its manufacturing and supply chain operations.

Segmental Insights

The Antibiotics segment is currently positioned as the fastest-growing category within the Global Biopharmaceutical Fermentation System Market. This rapid expansion is primarily driven by the escalating global prevalence of infectious diseases and the critical necessity to combat antimicrobial resistance. As bacteria evolve to withstand existing treatments, pharmaceutical manufacturers are intensifying their investment in advanced fermentation technologies to develop novel and more potent antibiotic compounds. These systems enable the precise metabolic engineering and scalable production required to meet the urgent worldwide demand for next-generation antimicrobial therapies, ensuring a steady supply of essential life-saving drugs.

Regional Insights

North America maintains a dominant position in the Global Biopharmaceutical Fermentation System Market, driven by an extensive network of biopharmaceutical manufacturers and superior research facilities. This leadership is underpinned by a rigorous yet supportive regulatory environment overseen by the U.S. Food and Drug Administration (FDA), which streamlines the approval process for new biologics. Additionally, significant federal funding through organizations such as the National Institutes of Health (NIH) accelerates innovation in therapeutic development. The region's sustained commitment to addressing chronic illnesses through precision medicine further amplifies the demand for reliable and scalable fermentation solutions.

Recent Developments

In April 2025, Thermo Fisher Scientific introduced the 5L DynaDrive Single-Use Bioreactor to address the evolving requirements of modern bioprocessing. This new bench-scale system was designed to bridge the gap between small-scale research and commercial manufacturing, offering scalability from 1 liter up to 5,000 liters. The company reported that the system delivered a 27% increase in productivity compared to traditional glass bioreactors. The launch aimed to assist contract development and manufacturing organizations as well as biopharmaceutical companies in streamlining their process development and accelerating the commercialization of therapies.
In November 2024, Sartorius Stedim Biotech inaugurated a new Center for Bioprocess Innovation in Marlborough, Massachusetts. This 63,000-square-foot facility was established to foster on-site collaboration and co-development with customers and external partners by utilizing the company's latest technologies in real-world bioprocess workflows. The center housed research and service laboratories designed to offer process development, optimization, and validation services. The President of Sartorius North America highlighted that the facility would leverage the region's robust innovation ecosystem to accelerate the path of new therapeutics to clinical trials.
In April 2024, Fujifilm Diosynth Biotechnologies announced a significant expansion of its large-scale cell culture bio-manufacturing facility in Holly Springs, North Carolina. The company committed an additional investment of $1.2 billion to this site, bringing the total project investment to over $3.2 billion. This expansion plan included the addition of eight 20,000-liter mammalian cell culture bioreactors by 2028, which would significantly bolster the facility's bulk drug substance production capacity. The initiative aimed to support the global manufacturing network and create hundreds of new highly skilled jobs in the region.
In March 2024, Getinge expanded its biopharmaceutical manufacturing portfolio by launching the Single-Use Production Reactor (SUPR) system. This new system was initially made available in 50-liter and 250-liter sizes, designed to assist operators in accelerating the time-to-market for life-saving medicines. The company utilized its extensive experience in bioreactor design to create a solution suitable for both pilot and GMP manufacturing applications. Key features included a click-n-go bag loading mechanism and a collapsible plastic 3D-printed impeller, which enhanced ease of use and sustainability by allowing for smaller packaging during transport.

Key Market Players

Agilent Technologies, Inc.
Thermo Fisher Scientific Inc
Lonza Group AG
Sartorius Stedim Biotech GmbH
Eppendorf SE
Danaher Corp
F Hoffmann-La Roche AG
Nova Biomedical Corp
Merck KGaA
Becton Dickinson & Co

By Product Type	By Application	By End User	By Region
Upstream Products (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others) Downstream Products (Filtration & Separation, Chromatography, Consumables and Accessories, Others)	Antibiotics Recombinant Proteins Others	Biopharmaceutical Industries Contract Research Organization Academic Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Biopharmaceutical Fermentation System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Fermentation System Market, By Product Type:

Upstream Products (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others)
Downstream Products (Filtration & Separation, Chromatography, Consumables and Accessories, Others)

Biopharmaceutical Fermentation System Market, By Application:

Antibiotics
Recombinant Proteins
Others

Biopharmaceutical Fermentation System Market, By End User:

Biopharmaceutical Industries
Contract Research Organization
Academic Research Institutes
Others

Biopharmaceutical Fermentation System Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Fermentation System Market.

Available Customizations:

Global Biopharmaceutical Fermentation System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Biopharmaceutical Fermentation System Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Fermentation System Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product Type (Upstream Products (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others), Downstream Products (Filtration & Separation, Chromatography, Consumables and Accessories, Others))

5.2.2. By Application (Antibiotics, Recombinant Proteins, Others)

5.2.3. By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

6. North America Biopharmaceutical Fermentation System Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product Type

6.2.2. By Application

6.2.3. By End User

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Biopharmaceutical Fermentation System Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product Type

6.3.1.2.2. By Application

6.3.1.2.3. By End User

6.3.2. Canada Biopharmaceutical Fermentation System Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product Type

6.3.2.2.2. By Application

6.3.2.2.3. By End User

6.3.3. Mexico Biopharmaceutical Fermentation System Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product Type

6.3.3.2.2. By Application

6.3.3.2.3. By End User

7. Europe Biopharmaceutical Fermentation System Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Product Type

7.2.2. By Application

7.2.3. By End User

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Biopharmaceutical Fermentation System Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product Type

7.3.1.2.2. By Application

7.3.1.2.3. By End User

7.3.2. France Biopharmaceutical Fermentation System Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product Type

7.3.2.2.2. By Application

7.3.2.2.3. By End User

7.3.3. United Kingdom Biopharmaceutical Fermentation System Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Product Type

7.3.3.2.2. By Application

7.3.3.2.3. By End User

7.3.4. Italy Biopharmaceutical Fermentation System Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Product Type

7.3.4.2.2. By Application

7.3.4.2.3. By End User

7.3.5. Spain Biopharmaceutical Fermentation System Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Product Type

7.3.5.2.2. By Application

7.3.5.2.3. By End User

8. Asia Pacific Biopharmaceutical Fermentation System Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Application

8.2.3. By End User

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Biopharmaceutical Fermentation System Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product Type

8.3.1.2.2. By Application

8.3.1.2.3. By End User

8.3.2. India Biopharmaceutical Fermentation System Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product Type

8.3.2.2.2. By Application

8.3.2.2.3. By End User

8.3.3. Japan Biopharmaceutical Fermentation System Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product Type

8.3.3.2.2. By Application

8.3.3.2.3. By End User

8.3.4. South Korea Biopharmaceutical Fermentation System Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Product Type

8.3.4.2.2. By Application

8.3.4.2.3. By End User

8.3.5. Australia Biopharmaceutical Fermentation System Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Product Type

8.3.5.2.2. By Application

8.3.5.2.3. By End User

9. Middle East & Africa Biopharmaceutical Fermentation System Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type

9.2.2. By Application

9.2.3. By End User

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Biopharmaceutical Fermentation System Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product Type

9.3.1.2.2. By Application

9.3.1.2.3. By End User

9.3.2. UAE Biopharmaceutical Fermentation System Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product Type

9.3.2.2.2. By Application

9.3.2.2.3. By End User

9.3.3. South Africa Biopharmaceutical Fermentation System Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product Type

9.3.3.2.2. By Application

9.3.3.2.3. By End User

10. South America Biopharmaceutical Fermentation System Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product Type

10.2.2. By Application

10.2.3. By End User

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Biopharmaceutical Fermentation System Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Product Type

10.3.1.2.2. By Application

10.3.1.2.3. By End User

10.3.2. Colombia Biopharmaceutical Fermentation System Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Product Type

10.3.2.2.2. By Application

10.3.2.2.3. By End User

10.3.3. Argentina Biopharmaceutical Fermentation System Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Product Type

10.3.3.2.2. By Application

10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Biopharmaceutical Fermentation System Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Agilent Technologies, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Thermo Fisher Scientific Inc

15.3. Lonza Group AG

15.4. Sartorius Stedim Biotech GmbH

15.5. Eppendorf SE

15.6. Danaher Corp

15.7. F Hoffmann-La Roche AG

15.8. Nova Biomedical Corp

15.9. Merck KGaA

15.10. Becton Dickinson & Co

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Biopharmaceutical Fermentation System Market in 2025?

Which is the dominating region in the Global Biopharmaceutical Fermentation System Market?

Which is the fastest growing segment in the Global Biopharmaceutical Fermentation System Market?

What is the expected growth rate of the Global Biopharmaceutical Fermentation System Market?